Exploring the Pharmacological Mechanism of Danzhi Xiaoyao Powder on ER-Positive Breast Cancer by a Network Pharmacology Approach

Evidence-based Complementary and Alternative Medicine

Volumn 2018, Issue , 2018, Pages

  Yang, Kailin ^a   Zeng, Liuting ^a   Ge, Jinwen ^a  

^a HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHINESE DRUG; DANZHI XIAOYAO POWDER; UNCLASSIFIED DRUG;

ARTICLE; CACO-2 CELL LINE; CANCER HORMONE THERAPY; CANCER PATIENT; CELL PROLIFERATION; CLINICAL PRACTICE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG TARGETING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE INTERACTION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INFLAMMATION; LONG TERM CARE; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAPK SIGNALING; MCF-7 CELL LINE; PI3K/AKT SIGNALING; PREDICTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; THERAPY EFFECT; TUMOR PROMOTION; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 85046258677     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2018/5059743     Document Type: Article

References (84)

1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortet- Tieulent, "Global cancer statistics, 2012," CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87-108, 2015.
2. L. Fan, K. Strasser-Weippl, J.-J. Li et al., "Breast cancer in China," The Lancet Oncology, vol. 15, no. 7, pp. e279-e289, 2014.
3. C. Sotiriou, S.-Y. Neo, L. M. McShane et al., "Breast cancer classification and prognosis based on gene expression profiles from a population-based study," Proceedings of the National Acadamy of Sciences of the United States of America, vol. 100, no. 18, pp. 10393-10398, 2003.
4. T. Sørlie, C. M. Perou, and R. Tibshirani, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications," Proceedings of the National Acadamy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869-10874, 2001.
5. K. Altundag and N. K. Ibrahimb, "Aromatase inhibitors in breast cancer: An overview," The Oncologist, vol. 11, no. 6, pp. 553-562, 2006.
6. T. N. Pathiraja, V. Stearns, and S. Oesterreich, "Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response," Journal of Mammary Gland Biology and Neoplasia, vol. 15, no. 1, pp. 35-47, 2010.
7. J. Russo and I.H. Russo, "Therole of estrogen in the initiation of breast cancer,"The Journal of SteroidBiochemistry andMolecular Biology, vol. 102, no. 1-5, pp. 89-96, 2006.
8. A. Howell, "Pure oestrogen antagonists for the treatment of advanced breast cancer," Endocrine-Related Cancer, vol. 13, no. 3, pp. 689-706, 2006.
9. E. Rock and A. DeMichele, "Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors," Journal of Nutrition, vol. 133, no. 11, pp. 3785S-3793S, 2003.
10. C. Oudin, F. Bonnetain, R. Boidot et al., "Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy," International Journal of Oncology, vol. 30, no. 5, pp. 1145-1151, 2007.
11. J. J. Tao, K. Visvanathan, and A. C. Wolff, "Long termside effects of adjuvant chemotherapy in patients with early breast cancer," The Breast Journal, vol. 24, supplement 2, pp. S149-S153, 2015.
12. A. M. Gonzalez-Angulo, F. Morales-Vasquez, and G. N. Hortobagyi, "Overview of resistance to systemic therapy in patients with breast cancer," Advances in Experimental Medicine and Biology, vol. 608, pp. 1-22, 2007.
13. B. Fisher, J. P. Costantino, C. K. Redmond, E. R. Fisher, D. L. Wickerham, and W. M. Cronin, "Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14," Journal of the National Cancer Institute, vol. 86, no. 7, pp. 527-537, 1994.
14. N. T. Telang, G. Li, D.W. Sepkovic, H. L. Bradlow, and G. Y. C. Wong, "Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer," Molecular Medicine Reports, vol. 5, no. 1, pp. 22-28, 2012.
15. N. Telang, G. Li, D. Sepkovic, H. L. Bradlow, and G. Y. C. Wong, "Comparative efficacy of extracts from lyciumbarbarum bark and fruit on estrogen receptor positive human mammary carcinomaMCF-7 cells," Nutrition and Cancer, vol. 66, no. 2, pp. 278-284, 2014.
16. G. Li, D. W. Sepkovic, H. L. Bradlow, N. T. Telang, and G. Y. C. Wong, "Lycium barbarum inhibits growth of estrogen receptor positive human breast cancer cells by favorably altering estradiol metabolism," Nutrition and Cancer, vol. 61, no. 3, pp. 408-414, 2009.
17. L. Yi, T. Pan, and W. Zou, "Relationship between traditionalChinesemedicine constitution types with chemotherapyinduced nausea and vomiting in patients with breast cancer: an observational study," BMC Complementary & Alternative Medicine, vol. 16, no. 1, p. 451, 2016.
18. N. Telang, G. Li, M. Katdare, D. Sepkovic, L. Bradlow, and G. Wong, "Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function," Oncology Letters, vol. 12, no. 5, pp. 3949-3957, 2016.
19. R. Li, L. P. Liu, Z. Wang et al., "Effect of Danzhi Xiaoyao San on Human Breasr Cancer Cell LineMCF-7 in NudeMice," Chinese Journal of Experimental Traditional Medical Formulae, vol. 22, pp. 78-81, 2016.
20. X. G. Dong, X. J. Li, and Y. J. Jia, "JIA Yingjie Danzhi Xiaoyao Powder in the Treatment of Breast Cancer," Journal of Practical Traditional Chinese Internal Medicine, vol. 5, pp. 11-12, 2014.
21. J. H. Chen, Professor Sun Guizhi 's Experience in Treating Breast Cancer with Syndrome Differentiation and Clinical Study, China Academy of Chinese medical Science, Beijing, China, 2012.
22. L. L. He and G. Z. Sun, "Sun Guizhi's experience of treating mammary cancer," Beijing Journal of Traditional Chinese Medicine, vol. 28, pp. 18-19, 2009.
23. H. Liao, L. K. Banbury, and D. N. Leach, "Effects and potential mechanisms of Danzhi Xiaoyao Pill on proliferation of MCF-7 human breast cancer cells in vitro," Chinese Journal of Integrative Medicine, vol. 14, no. 2, pp. 128-131, 2008.
24. L. Wu, Y. Wang, J. Nie, X. Fan, and Y. Cheng, "A network pharmacology approach to evaluating the efficacy of chinese medicine using genome-wide transcriptional expression data," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 915343, 2013.
25. A. L. Hopkins, "Network pharmacology: the next paradigm in drug discovery," Nature Chemical Biology, vol. 4, no. 11, pp. 682-690, 2008.
26. H. Tang, S. He, X. Zhang et al., "A network pharmacology approach to uncover the pharmacological mechanism of xuanhusuo powder on osteoarthritis," Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 3246946, 10 pages, 2016.
27. M.N. Trame, K. Biliouris, L. J. Lesko, and J. T. Mettetal, "Systems pharmacology to predict drug safety in drug development," European Journal of Pharmaceutical Sciences, vol. 94, pp. 93-95, 2016.
28. H. Liu, L. Zeng, K. Yang, and G. Zhang, "A network pharmacology approach to explore the pharmacological mechanism of xiaoyao powder on anovulatory infertility," Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 2960372, 2016.
29. L. Zeng and K. Yang, "Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach," Journal of Ethnopharmacology, vol. 199, pp. 68-85, 2017.
30. M. Danhof, "Systems pharmacology -Towards the modeling of network interactions," European Journal of Pharmaceutical Sciences, vol. 94, pp. 4-14, 2016.
31. F.-P. Chen, C.-M. Chang, S.-J. Hwang, Y.-C. Chen, and F.- J. Chen, "Chinese herbal prescriptions for osteoarthritis in Taiwan: analysis of national health insurance dataset," BMC Complementary and Alternative Medicine, vol. 14, article 91, 2014.
32. J. Ru, P. Li, J. Wang et al., "TCMSP: a database of systems pharmacology for drug discovery from herbal medicines," Journal of Cheminformatics, vol. 6, no. 1, article 13, 2014.
33. J. Zhang, Y. Li, S.-S. Chen et al., "Systems pharmacology dissection of the anti-inflammatory mechanism for the medicinal herb Folium eriobotryae," International Journal of Molecular Sciences, vol. 16, no. 2, pp. 2913-2941, 2015.
34. X. Xu, W. Zhang, C. Huang et al., "Anovel chemometric method for the prediction of human oral bioavailability," International Journal ofMolecular Sciences, vol. 13, no. 6, pp. 6964-6982, 2012.
35. R. Ano, Y. Kimura, M. Shima, R. Matsuno, T. Ueno, and M. Akamatsu, "Relationships between structure and highthroughput screening permeability of peptide derivatives and related compounds with artificial membranes: Application to prediction of Caco-2 cell permeability," Bioorganic & Medicinal Chemistry, vol. 12, no. 1, pp. 257-264, 2004.
36. G. X. Hu, C. H. Zhang, W. N. Zhao, and Q. S. Yu, "QSPR study on the permeability of drugs across Caco-2 monolayer," Journal of Zhejiang University, vol. 3, pp. 304-308, 2009.
37. W. P. Walters and M. A. Murcko, "Prediction of 'drug-likeness'," Advanced Drug Delivery Reviews, vol. 54, no. 3, pp. 255-271, 2002.
38. D. Metodiewa, A. Kochman, and S. Karolczak, "Evidence for antiradical and antioxidant properties of four biologically active N,N-diethylamioethyl ethers of flavanone oximes: A comparisonwith natural polyphenolic flavonoid (rutin) action," International Journal of Biochemistry andMolecular Biology, vol. 41, no. 5, pp. 1067-1075, 1997.
39. L. L. Chen, Y.H. Wang, J. Qi, T. X. Dong, D. N. Zhu, and B. Y. Yu, "Identification and Determination of Absorbed Components of Danggui-Shaoyao-San in Rat Plasma," Chinese Journal of Natural Medicines, vol. 9, pp. 363-368, 2011.
40. Q. L. Tian, Y. P. Guan, B. Zhang, and H. Z. Liu, "Research Advances on Pharmacological Activities of Components in Licorice," Natural Product Research and Development, vol. 2, pp. 343-347, 2006.
41. X. Liu, S. Ouyang, B. Yu et al., "PharmMapper server: a web server for potential drug target identification using pharmacophoremapping approach," Nucleic Acids Research, vol. 38, no. 2, pp.W609-W614, 2010.
42. A. Hamosh, A. F. Scott, J. S. Amberger, C. A. Bocchini, and V. A. McKusick, "Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders," Nucleic Acids Research, vol. 33, pp. D514-D517, 2005.
43. D. Szklarczyk, A. Franceschini, S. Wyder et al., "STRING v10: protein-protein interaction networks, integrated over the tree of life," Nucleic Acids Research, vol. 43, pp. D447-D452, 2015.
44. P. V. Missiuro, K. Liu, L. Zou et al., "Information flow analysis of interactome networks," PLoS Computational Biology, vol. 5, no. 4, Article ID e1000350, 2009.
45. G. D. Bader and C. W. V. Hogue, "An automated method for finding molecular complexes in large protein interaction networks," BMC Bioinformatics, vol. 4, no. 1, p. 2, 2003.
46. A. Barabási, N. Gulbahce, and J. Loscalzo, "Network medicine: a network-based approach to human disease," Nature Reviews Genetics, vol. 12, no. 1, pp. 56-68, 2011.
47. D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," Nature Protocols, vol. 4, no. 1, pp. 44-57, 2009.
48. B. Hanstein, S. Djahansouzi, P. Dall, M. W. Beckmann, and H. G. Bender, "Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer," European Journal of Endocrinology, vol. 150, no. 3, pp. 243-255, 2004.
49. J. S. Tobias, "Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women," The International Journal of Biochemistry & Cell Biology, vol. 36, no. 11, pp. 2112-2119, 2004.
50. S. Borgquist, C. Holm, M. Stendahl, L. Anagnostaki, G. Landberg, and K. Jirström, "Oestrogen receptors α and β show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer," Journal of Clinical Pathology, vol. 61, no. 2, pp. 197-202, 2008.
51. V. Kumar and P. Chambon, "The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer," Cell, vol. 55, no. 1, pp. 145-156, 1988.
52. J. C. Reese and B. S. Katzenellenbogen, "Differential DNAbinding abilites of estrogen receptor occupied with two classes of antiestrogens: Studies using human estrogen receptor overexpressed in mammalian cells," Nucleic Acids Research, vol. 19, no. 23, pp. 6595-6602, 1991.
53. N. F. Smirnova, C. Fontaine, M. Buscato et al., "The activation function-1 of estrogen receptor alpha prevents arterial neointima development through a direct effect on smooth muscle cells," Circulation Research, vol. 117, no. 9, pp. 770-777, 2015.
54. C. K. Osborne and R. Schiff, "Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer," The Breast Journal, vol. 12, no. 6, pp. 362-367, 2003.
55. S. A. W. Fuqua, R. Schiff, I. Parra et al., "Expression of wildtype estrogen receptor β and variant isoforms in human breast cancer," Cancer Research, vol. 59, no. 21, pp. 5425-5428, 1999.
56. E. J. Filardo, J. A. Quinn, A. Raymond Frackelton Jr., and K. I. Bland, "Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis," Molecular Endocrinology, vol. 16, no. 1, pp. 70-84, 2002.
57. M. Bartucci, C. Morelli, L. Mauro, S. Ando', and E. Surmacz, "Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ERnegative MDA-MB-231 breast cancer cells," Cancer Research, vol. 61, no. 18, pp. 6747-6754, 2001.
58. S. Oesterreich, P. Zhang, R. L. Guler et al., "Re-expression of estrogen receptor α in estrogen receptor α-negativeMCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling anal growth," Cancer Research, vol. 61, no. 15, pp. 5771-5777, 2001.
59. R. B. Dickson and G. M. Stancel, "Estrogen receptor-mediated processes in normal and cancer cells," JNCI Monographs, vol. 27, pp. 135-145, 2000.
60. M. A. Shupnik, "Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation," Oncogene, vol. 23, no. 48, pp. 7979-7989, 2004.
61. J. Matthews, B. Wihlén, M. Tujague, J. Wan, A. Ström, and J.-A. Gustafsson, "Estrogen receptor (ER) β modulates ER α-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters," Molecular Endocrinology, vol. 20, no. 3, pp. 534-543, 2006.
62. E. J. Filardo and P. Thomas, "GPR30: a seven-transmembranespanning estrogen receptor that triggers EGF release," Trends in Endocrinology & Metabolism, vol. 16, no. 8, pp. 362-367, 2005.
63. C. B. Weldon, S. Elliott, Y. Zhu et al., "Regulation of estrogenmediated cell survival and proliferation by p160 coactivators," Surgery, vol. 136, no. 2, pp. 346-354, 2004.
64. M. Akahane, T. Akahane, S. L. Matheny, A. Shah, E. Okajima, and U. P. Thorgeirsson, "Vascular endothelial growth factor- D Is a survival factor for human breast carcinoma cells," International Journal ofCancer, vol. 118, no. 4, pp. 841-849, 2006.
65. V.-J. Bardou, G. Arpino, R. M. Elledge, C. K. Osborne, and G. M. Clark, "Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases," Journal of Clinical Oncology, vol. 21, no. 10, pp. 1973-1979, 2003.
66. X. Cui, P. Zhang, W. Deng et al., "Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer," Molecular Endocrinology, vol. 17, no. 4, pp. 575-588, 2003.
67. S. Hiscox, L. Morgan, T. P. Green, D. Barrow, J. Gee, and R. I. Nicholson, "Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells," Breast Cancer Research and Treatment, vol. 97, no. 3, pp. 263-274, 2006.
68. G. Castoria, A. Migliaccio, A. Bilancio et al., "PI3-kinase in concert with Src promotes the S-phase entry of oestradiolstimulated MCF-7 cells," EMBO Journal, vol. 20, no. 21, pp. 6050-6059, 2001.
69. X.-D. Zhu, "Correlating signal transduction pathway of mammary epithelial stem cells to breast cancer," Journal of Clinical Rehabilitative Tissue Engineering Research, vol. 12, no. 21, pp. 4151-4154, 2008.
70. J. A. Menendez, I. Mehmi, E. Atlas, R. Colomer, and R. Lupu, "Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53- p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NFkappaB.," International Journal of Oncology, vol. 24, no. 3, pp. 591-608, 2004.
71. J. Dai, M. A. Miller, N. J. Everetts et al., "Elimination of quiescent slow-cycling cells via reducing quiescence depth by natural compounds purified from Ganoderma lucidum," Oncotarget , vol. 8, no. 8, pp. 13770-13781, 2017.
72. S. H. Jen, M. P. Wei, and A. C. Yin, "The Combinatory Effects of Tamoxifen on Ishikawa and MCF-7 Cell Lines," Natural Product Communications, vol. 10, pp. 1573-1576, 2015.
73. R. Hong, M.-H. Shen, X.-H. Xie, and S.-M. Ruan, "Inhibition of breast cancer metastasis via PITPNM3 by pachymic acid," Asian Pacific Journal of Cancer Prevention, vol. 13, no. 5, pp. 1877-1880, 2012.
74. Y. H. Ju, L. M. Clausen, K. F. Allred, A. L. Almada, and W. G. Helferich, "β-Sitosterol, β-Sitosterol Glucoside, and a Mixture of β-Sitosterol and β-SitosterolGlucosideModulate theGrowth of Estrogen-Responsive Breast Cancer Cells in Vitro and in Ovariectomized Athymic Mice," Journal of Nutrition, vol. 134, no. 5, pp. 1145-1151, 2004.
75. S.-H. Kim, K.-A. Hwang, and K.-C. Choi, "Treatment with kaempferol suppresses breast cancer cell growth caused by estrogen and triclosan in cellular and xenograft breast cancer models,"The Journal of NutritionalBiochemistry, vol. 28, pp. 70-82, 2016.
76. A. Rivera Rivera, L. Castillo-Pichardo, Y. Gerena, and S. Dharmawardhane, "Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade," PLoS ONE, vol. 11, no. 6, p. e0157251, 2016.
77. S. Balakrishnan, F. A. Bhat, P. Raja Singh et al., "Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2-mediated pathway in breast cancer," Cell Proliferation, vol. 49, no. 6, pp. 678-697, 2016.
78. N. Wang, Z. Wang, Y. Wang et al., "Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation," Oncotarget , vol. 6, no. 12, pp. 9854-9876, 2015.
79. S. Hu, L. Huang, L. Meng, H. Sun, W. Zhang, and Y. Xu, "Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen-activated protein kinase kinase signaling pathways,"Molecular Medicine Reports, vol. 12, no. 5, pp. 6745-6751, 2015.
80. D. G. Chryssanthi, P. G. Dedes, N. K. Karamanos, P. Cordopatis, and F. N. Lamari, "Crocetin inhibits invasiveness of MDA-MB- 231 breast cancer cells via downregulation ofmatrixmetalloproteinases," Planta Medica, vol. 77, no. 2, pp. 146-151, 2011.
81. L. Yu, J. Ma, J. Han et al., "Licochalcone B arrests cell cycle progression and induces apoptosis in human breast cancer MCF-7 cells," Recent Patents on Anti-Cancer Drug Discovery, vol. 11, no. 4, pp. 444-452, 2016.
82. R. Zhou, L. Xu, M. Ye, M. Liao, H. Du, and H. Chen, "Formononetin inhibits migration and invasion of MDA-MB- 231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways," Hormone and Metabolic Research, vol. 46, no. 11, pp. 753-760, 2014.
83. S. Tamir, M. Eizenberg, D. Somjen et al., "Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells," Cancer Research, vol. 60, no. 20, pp. 5704-5709, 2000.
84. H. Wang, L. Tao, K. Qi et al., "Quercetin reverses tamoxifen resistance in breast cancer cells," Journal of B.U.ON., vol. 20, no. 3, pp. 707-713, 2015.